Overview

Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML)

Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical study is to find out whether continued therapy with decitabine after achieving a remission in acute myeloid leukemia (AML) patients can help prolong the remission and prevent relapse of the disease.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Eisai Inc.
Treatments:
Azacitidine
Decitabine